Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

Generac Holdings (NYSE:GNRC) has surged 56.65% year-to-date, with shares climbing 36.35% over the past month and 20.51% in the last week. Incredibly, that means Generac is now outperforming 99% of all ...

Arizona turns 114 on Saturday, with free museum open houses, special exhibits and state park events across Southern Arizona ...

An estimated 1.7 million women in Bangladesh underwent unnecessary caesarean sections (CS) in 2025, exposing mothers and ...

Healthcare Services Group, Inc. (NASDAQ:HCSG) Q4 2025 Earnings Call Transcript February 11, 2026 Healthcare Services Group, Inc. beats earnings expectations. Reported EPS is $0.4362, expectations were ...

Leading diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today that the U.S. division of its ...

Cutaneous sarcoidosis occurs in between 20% and 35% of systemic sarcoidosis patients and there is no approved therapy.

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...

Vancouver, British Columbia - Newsfile Corp. - February 9, 2026 - Intrepid Metals Corp. (TSXV: INTR) (OTCQB: IMTCF) ( ...

KUALA LUMPUR, Feb 12 — Proton has officially taken the drapes off the new 2026 Proton S70 MC. The newly ...

Q4 2025 earnings call recap: revenue, EPS, margins, cash flow and Q1 2026 outlook, plus Medical and Semi-Cap momentum—read now.